A pilot study of mild induced hypothermia for severe falciparum malaria

niversity of Oxford (UK)0 个研究点目标入组 10 人开始时间: 2013年10月23日最近更新: 2020年8月17日

适应症

试验速览

暂无简介。

•1. Age 16-60 years
•2. Informed consent obtained (plus parental/guardian assent if 16 or 17 years old)
•3. Time of commencement of artesunate =18 hrs before therapy
•4. Any level of Plasmodium falciparum parasitemia, and one or more of the following criteria:
•4.1. Acute renal failure (creatinine >265umol/L)
•4.2. Hyperbilirubinemia (total bilirubin >50 umol/L) with either renal impairment (creatinine >130umol/L) or parasitemia of >100,000 parasites/uL
•4.3. Blackwater fever
•4.4. Hyperparasitemia (>10% parasitised red cells)
•4.5. Cerebral malaria (Glasgow coma score <11)
•4.6. Hypoglycemia
•4.7. Respiratory distress (RR >32)
•4.8. Venous bicarbonate 12-15 meq/L (pilot phase) or 8-15 meq/L

•1. Pregnancy or lactation
•2. Diabetes
•3. Serious pre-existing disease (cardiac, hepatic, kidney)
•4. History of contraindications to hypothermia (Raynaud?s disease, Cryoglobulinemia, Sickle Cell disease, serum cold agglutinins, Buerger?s disease)
•5. Bleeding disorders (e.g., hemophilia)
•6. An intranasal obstruction or known skull base fracture

发起方

niversity of Oxford (UK)